| Document |
Document Title |
|
WO/2024/100203A1 |
Methods of cancer treatment comprise administration of a modified natural killer (NK) cell in combination with an immunomodulatory drug. Also described are compositions comprising a combination of a modified NK cell and an immunomodulato...
|
|
WO/2024/100421A1 |
The invention relates to therapeutic uses of SARM1 agents (e.g. molecule that causes neurodegeneration and/or neuronal dysfunction in a SARM1 -dependent manner) such as Vacor, metabolites, analogs, and derivatives thereof for treating an...
|
|
WO/2024/102342A1 |
The present invention relates to a process of removing free-unlabeled radionuclides from a radiopharmaceutical prior to administering the radiopharmaceutical to the patient using size-exclusion or ion-exchange mechanisms.
|
|
WO/2024/098894A1 |
Provided are a tumor-targeted imaging nano assembly, a preparation method therefor, and use thereof. The nano assembly comprises an active targeting unit, an imaging signal unit, and metal ions. The active targeting unit is coordinated w...
|
|
WO/2024/100250A1 |
In a first aspect, the invention relates to a combination of at least one menin inhibitor with at least one immunoproteasome inhibitor for use as medicament, preferably for use in the treatment of leukemia. A second aspect of the inventi...
|
|
WO/2024/101345A1 |
Provided is an agent containing an RGMa inhibition substance, the agent being for suppressing accumulation of abnormal protein aggregates or for inhibiting uptake of abnormal proteins by nerve cells, particularly for preventing or treati...
|
|
WO/2024/102704A2 |
Provided are methods and compositions for use in cancer immunotherapies. In various embodiments, the compositions include functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iP...
|
|
WO/2024/101965A1 |
The present disclosure pertains to a pharmaceutical combination for treating and/or preventing cancer and a method and use thereof. Specifically, the present disclosure involves a method for inhibiting tumor growth by combining a substan...
|
|
WO/2024/101406A1 |
The present invention provides a prophylactic and/or therapeutic agent for non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) or liver cancer, the agent containing a material for inhibiting the expression or f...
|
|
WO/2024/099363A1 |
Disclosed are a pharmaceutical composition of a receptor-interacting protein 2 (RIP2) inhibitor in combination with an immune checkpoint inhibitor and use thereof. The present invention provides a pharmaceutical composition comprising an...
|
|
WO/2024/036290A3 |
The present disclosure is directed to isolated cell populations comprising stable regulatory T cells and methods of producing the same, further wherein the isolated population of cells comprising stable CD4+ T regulatory cells (T regs) i...
|
|
WO/2024/099272A1 |
A method for treating IgA nephropathy and a pharmaceutical composition comprising an endothelin receptor antagonist and a glucocorticoid.
|
|
WO/2024/100236A1 |
The present specification relates to the use of an AKT inhibitor, a PI3K-α inhibitor or an mTOR (such as mTORC1) inhibitor in combination with a KDM5C inhibitor to treat cancer, for example breast cancer. Also described is a pharmaceuti...
|
|
WO/2024/101382A1 |
The present disclosure addresses the problem of providing a novel composition to be used in immune checkpoint regulation. One aspect of the present disclosure provides a composition which is to be used in immune checkpoint regulation and...
|
|
WO/2024/100285A1 |
The present invention relates to agents and methods for the treatment of cognitive disorders. The present invention also relates to methods of screening for agents which can be used to treat cognitive disorders. The present invention als...
|
|
WO/2024/097206A1 |
The present invention relates to Compound (A), pharmaceutically acceptable salts thereof, methods of making, and use thereof optionally in combination with one or more additional therapeutic agents for the treatment of disease.
|
|
WO/2024/097868A1 |
This disclosure relates to the structure-- activity relationships for 4-phosphoryloxy-N,N-dimethyltryptamine (psilocybin), 4-phosphoryloxy-N-methyltryptamine (baeocystin), and 4-phosphoryloxy-N,N,N-trimethyltryptamine (aeruginascin), as ...
|
|
WO/2024/098009A1 |
Compositions and methods for treating or preventing a condition related to myocardial infarction and infarct expansion, extension, and/or dilation following a cardiovascular disorder incident (e.g., post-myocardial infarction) using an e...
|
|
WO/2024/095279A1 |
The present invention discloses synergistic herbal compositions comprising combination of a first ingredient selected from Centella asiatica extract containing at least one component selected from magnesium salt or complex of asiatic aci...
|
|
WO/2024/096133A1 |
The present invention provides a cell-to-cell human T-lymphotropic virus type 1 (HTLV-1) infection inhibitor that contains a substance that inhibits interaction between N-acetyllactosamine (LacNAc) and galectin-3 (Gal-3).
|
|
WO/2024/095992A1 |
The present invention addresses the problem of providing a novel means for suppressing renal hypofunction, the means being capable of fundamentally improving diseases associated with renal hypofunction, including chronic kidney disease (...
|
|
WO/2024/097653A1 |
Methods for treatment of myeloproliferative neoplasms are provided, particularly in patients with poor bone marrow functioning, and difficult to treat human patients such as those with relapsed or refractory disease. The disclosed method...
|
|
WO/2024/097721A1 |
The disclosure relates to the use of inhibitors of phosphoinositide 3-kinase (PI3K) that target allosteric and orthosteric pockets of PI3K in methods of treating, preventing, or ameliorating a disease, or disorder, (or uses in the treatm...
|
|
WO/2024/097908A1 |
The present invention is generally directed to a potent therapy for SARS-CoV-2 (CoV2) disease which involve combinations of agents. Here we describe combinations of 2 drugs wherein the combination inhibits CoV2 replication through one or...
|
|
WO/2024/097636A1 |
This disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Kα) for use in combination with additional therapeuti...
|
|
WO/2024/095118A1 |
The present invention relates to dosing regimens of CSF-1R inhibitors for treating amyotrophic lateral sclerosis. More particularly, the present invention relates to a CSF-1R inhibitor for use in the treatment of amyotrophic lateral scle...
|
|
WO/2024/097804A1 |
The present application provides methods of treating a cancer in an individual that involves administering to the individual a tyrosine kinase inhibitor and a pro-inflammatory agent (such as a TLR agonist, a STING activator, a radiation ...
|
|
WO/2024/094844A1 |
The present disclosure relates to oral formulations of an n-pyridinyl acetamide derivative, and the use of such formulations in the treatment of interstitial lung diseases.
|
|
WO/2024/098005A1 |
This present invention provides a pharmaceutical composition comprising one or more ACAT inhibitors and one or more GLP-lRAs. It also provides a method for controlling body weight comprising co-administering to a subject in need one or m...
|
|
WO/2024/097878A1 |
Provided herein are methods of predicting a risk of developing an immune-related adverse event (irAE) from an immune checkpoint inhibitor (ICI) therapy. The methods include the classification of T cell receptor p genes as productive TCRÎ...
|
|
WO/2024/096122A1 |
The present disclosure provides a microbiome for the purpose of improving the response rate of an immune checkpoint inhibitor. Specifically, the present disclosure provides a microorganism wherein at least one gene among a flagella-formi...
|
|
WO/2024/091299A1 |
Described herein are methods for disease or disorder associated with GABA transporter 1 (GAT-1) dysfunction. In one aspect described herein, the disease or disorder is associated with one or more solute carrier Family 6 Member 1 (SLC6A1)...
|
|
WO/2024/089702A1 |
The present invention relates to an improved process for the preparation of (N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylpheny
l)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-d
iamine compound of formula-1 and its sa...
|
|
WO/2024/088309A1 |
Provided are a multispecific antibody binding to GPRC5D and CD3 antigens, an antigen binding molecule thereof, a nucleic acid molecule encoding the multispecific antibody and the antigen binding molecule thereof, a vector containing the ...
|
|
WO/2024/092205A1 |
The general field of the present disclosure are novel approaches to the treatment of Alzheimer's and other neurodegenerative disorders using novel therapeutics comprising SHIP1 phosphatase inhibitors. Specifically, the invention provides...
|
|
WO/2024/089247A1 |
The present invention relates to a compound for treatment of neuropathic pain. It also relates to pharmaceutical compositions thereof, as well as methods of treatment of neuropathic pain.
|
|
WO/2024/087673A1 |
An antiplatelet drug, comprising a platelet inhibitory molecule, a linker, and a capture group. The capture group is a functional group of click chemistry reaction. The antiplatelet drug has good antiplatelet activity, and can be used in...
|
|
WO/2024/092269A1 |
The present invention relates to pharmaceutical formulations for kratom extract and mitragynine, which is the major alkaloid extracted from kratom, and use methods thereof for treatment of osteoarthritis in canine subjects.
|
|
WO/2024/090329A1 |
The present inventors have found that a pyridoxal synthetic enzyme Pyridoxamine-5'-phosphate oxidase (PNPO) acts as an oxygen sensing mechanism for a novel pathway that is independent from an HIF pathway in chronic hypoxia. A pharmaceuti...
|
|
WO/2024/092240A1 |
The present disclosure relates to the use of an endothelin receptor antagonist, or a pharmaceutically acceptable salt thereof, and isolated antibodies, including antigen-binding fragments thereof, which bind human APRIL for the treatment...
|
|
WO/2024/006460A9 |
Biomarkers and machine learning techniques to identify biomarkers are disclosed herein. In one particular implementation, the present disclosure relates to the identification of biomarkers to be used in the detection and diagnosis of LD....
|
|
WO/2024/088712A1 |
The present invention relates to mGluR5 antagonists, or compounds 4-[5-[(rac)-1-[5-(3- Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol
-3-yl]pyridine (TT00), or a pharmaceutically acceptable salt thereof, enantiomer, isotope...
|
|
WO/2024/089013A1 |
The invention relates to a combination of a PARP inhibitor with Omomyc, a functionally equivalent variant thereof, a conjugate comprising Omomyc or said functionally equivalent variant, a polynucleotide encoding said polypeptides, a vect...
|
|
WO/2024/090571A1 |
Provided are: a method for detecting immune-mediated inflammatory diseases characterized by an increase in the expression of MMP12 in a subject; a diagnostic drug containing a substance that specifically interacts with MMP12; and a thera...
|
|
WO/2024/089046A1 |
The present invention relates to a pharmaceutical composition suitable for an intra-articular injection comprising an anesthetic agent and an immediate or controlled release dosage form comprising colchicine. It further relates to a phar...
|
|
WO/2024/091863A1 |
Therapies and regimens for treating chronic diseases, disorders, and conditions that have a plurality of intervention targets and/or therapeutic targets are provided. Therapies include administration combinatorial regimens, and administr...
|
|
WO/2024/046471A9 |
The present application provides a class of novel compounds having a USP1 inhibitory activity as shown in formula (II'), pharmaceutical compositions comprising the compounds, useful intermediates for preparing the compounds, and a method...
|
|
WO/2024/090521A1 |
Provided is a pharmaceutical composition for treating and/or preventing renal cystic ciliopathy, the composition containing a retinoic acid receptor (RAR) agonist.
|
|
WO/2024/091624A1 |
Pharmaceutical formulations, particularly solid oral dosage forms (e.g., tablets) comprising (i) the compound of Formula I in an amount of about 40 wt% to about 70 wt%, (ii) a filler, (iii) a disintegrating agent, (iv) and a lubricant ar...
|
|
WO/2024/087265A1 |
A protein inhibitor, a reagent set, and a use thereof. The protein inhibitor is an inhibitor for inhibiting a CILK1 protein; the protein inhibitor is CILK1-C28 or CILK1-C30; the use of the protein inhibitor is to apply the protein inhibi...
|
